APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Angiotensin Receptor Blockers (ARBs)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Angiotensin Receptor Blockers (ARBs) Market Outlook and Growth Opportunities 2026

Report ID 173963710421 December 2025193 pages

Choose your research edition.

Industry ResearchAngiotensin Receptor Blockers (ARBs) Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiotensin Receptor Blockers (ARBs) Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Angiotensin Receptor Blockers (ARBs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiotensin Receptor Blockers (ARBs) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiotensin Receptor Blockers (ARBs) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Angiotensin Receptor Blockers (ARBs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Angiotensin Receptor Blockers (ARBs) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Angiotensin Receptor Blockers (ARBs) market include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiotensin Receptor Blockers (ARBs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiotensin Receptor Blockers (ARBs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiotensin Receptor Blockers (ARBs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiotensin Receptor Blockers (ARBs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiotensin Receptor Blockers (ARBs) Segment by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

Angiotensin Receptor Blockers (ARBs) Segment by Type

Valsartan

Telmisartan

Losartan

Irbesartan

Olmesartan

Azilsartan

Angiotensin Receptor Blockers (ARBs) Segment by Application

Cardiovascular Diseases

Kidney Diseases

Hypertension

Other

Angiotensin Receptor Blockers (ARBs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Angiotensin Receptor Blockers (ARBs) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Angiotensin Receptor Blockers (ARBs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Angiotensin Receptor Blockers (ARBs) significant trends, drivers, influence factors in global and regions.

6. To analyze Angiotensin Receptor Blockers (ARBs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Receptor Blockers (ARBs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Receptor Blockers (ARBs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Receptor Blockers (ARBs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiotensin Receptor Blockers (ARBs) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Angiotensin Receptor Blockers (ARBs) industry.

Chapter 3: Detailed analysis of Angiotensin Receptor Blockers (ARBs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Angiotensin Receptor Blockers (ARBs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Angiotensin Receptor Blockers (ARBs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Angiotensin Receptor Blockers (ARBs) Industry Trends Table 2. Angiotensin Receptor Blockers (ARBs) Industry Drivers Table 3. Angiotensin Receptor Blockers (ARBs) Industry Opportunities and Challenges Table 4. Angiotensin Receptor Blockers (ARBs) Industry Restraints Table 5. Global Angiotensin Receptor Blockers (ARBs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Angiotensin Receptor Blockers (ARBs) Revenue Share by Company (2021-2026) Table 7. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Company (2021-2026) Table 9. Global Angiotensin Receptor Blockers (ARBs) Average Price (US$/ton) of Company (2021-2026) Table 10. Global Angiotensin Receptor Blockers (ARBs) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Angiotensin Receptor Blockers (ARBs) Key Company Manufacturing Base & Headquarters Table 12. Global Angiotensin Receptor Blockers (ARBs) Company, Product Type & Application Table 13. Global Angiotensin Receptor Blockers (ARBs) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiotensin Receptor Blockers (ARBs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Valsartan Table 18. Significant Companies of Telmisartan Table 19. Significant Companies of Losartan Table 20. Significant Companies of Irbesartan Table 21. Significant Companies of Olmesartan Table 22. Significant Companies of Azilsartan Table 23. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 24. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2021-2026) & (k tons) Table 25. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2027-2032) & (k tons) Table 26. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Type (2021-2026) Table 27. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Type (2027-2032) Table 28. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type (2021-2026) Table 32. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Cardiovascular Diseases Table 34. Significant Companies of Kidney Diseases Table 35. Significant Companies of Hypertension Table 36. Significant Companies of Other Table 37. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 38. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2021-2026) & (k tons) Table 39. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2027-2032) & (k tons) Table 40. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Application (2021-2026) Table 41. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Application (2027-2032) Table 42. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application (2021-2026) Table 46. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application (2027-2032) Table 47. Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 48. Global Angiotensin Receptor Blockers (ARBs) Sales by Region (2021-2026) & (k tons) Table 49. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Region (2021-2026) Table 50. Global Angiotensin Receptor Blockers (ARBs) Sales by Region (2027-2032) & (k tons) Table 51. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Region (2027-2032) Table 52. Global Angiotensin Receptor Blockers (ARBs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Region (2021-2026) Table 55. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Region (2027-2032) Table 57. Global Angiotensin Receptor Blockers (ARBs) Market Average Price (US$/ton) by Region (2021-2026) Table 58. Global Angiotensin Receptor Blockers (ARBs) Market Average Price (US$/ton) by Region (2027-2032) Table 59. Global Angiotensin Receptor Blockers (ARBs) Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 60. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026) & (k tons) Table 62. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Country (2021-2026) Table 63. Global Angiotensin Receptor Blockers (ARBs) Sales by Country (2027-2032) & (k tons) Table 64. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Country (2027-2032) Table 65. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Angiotensin Receptor Blockers (ARBs) Sales Value Market Share by Country (2021-2026) Table 67. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Angiotensin Receptor Blockers (ARBs) Sales Value Market Share by Country (2027-2032) Table 69. Teva Pharmaceutical Company Information Table 70. Teva Pharmaceutical Business Overview Table 71. Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 73. Teva Pharmaceutical Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Sanofi Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 78. Sanofi Recent Development Table 79. Jhonson and Johnson Company Information Table 80. Jhonson and Johnson Business Overview Table 81. Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 83. Jhonson and Johnson Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. Novartis Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 88. Novartis Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Merck Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 93. Merck Recent Development Table 94. Eli Lilly Company Information Table 95. Eli Lilly Business Overview Table 96. Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 98. Eli Lilly Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Pfizer Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 103. Pfizer Recent Development Table 104. GSK Company Information Table 105. GSK Business Overview Table 106. GSK Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. GSK Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 108. GSK Recent Development Table 109. Bayer Company Information Table 110. Bayer Business Overview Table 111. Bayer Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 112. Bayer Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 113. Bayer Recent Development Table 114. Bristol-Myers Squibb Company Information Table 115. Bristol-Myers Squibb Business Overview Table 116. Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 117. Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 118. Bristol-Myers Squibb Recent Development Table 119. Astra Zeneca Company Information Table 120. Astra Zeneca Business Overview Table 121. Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 122. Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 123. Astra Zeneca Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Angiotensin Receptor Blockers (ARBs) Distributors List Table 127. Angiotensin Receptor Blockers (ARBs) Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Angiotensin Receptor Blockers (ARBs) Product Image Figure 2. Global Angiotensin Receptor Blockers (ARBs) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Angiotensin Receptor Blockers (ARBs) Sales (2021-2032) & (k tons) Figure 5. Global Angiotensin Receptor Blockers (ARBs) Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Angiotensin Receptor Blockers (ARBs) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Valsartan Image Figure 10. Telmisartan Image Figure 11. Losartan Image Figure 12. Irbesartan Image Figure 13. Olmesartan Image Figure 14. Azilsartan Image Figure 15. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 16. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Type (2021-2032) Figure 18. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type (2021-2032) Figure 21. Cardiovascular Diseases Image Figure 22. Kidney Diseases Image Figure 23. Hypertension Image Figure 24. Other Image Figure 25. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 26. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Application (2021-2032) Figure 28. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application (2021-2032) Figure 31. Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 32. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Angiotensin Receptor Blockers (ARBs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032) & (US$ Million) Figure 36. North America Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032) & (US$ Million) Figure 42. South America Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Angiotensin Receptor Blockers (ARBs) Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Angiotensin Receptor Blockers (ARBs) Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Valsartan
  • Telmisartan
  • Losartan
  • Irbesartan
  • Olmesartan
  • Azilsartan
Applications
  • Cardiovascular Diseases
  • Kidney Diseases
  • Hypertension
  • Other
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032)
  4. 1.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume (2021-2032)
  5. 1.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Angiotensin Receptor Blockers (ARBs) Market Dynamics
  1. 2.1 Angiotensin Receptor Blockers (ARBs) Industry Trends
  2. 2.2 Angiotensin Receptor Blockers (ARBs) Industry Drivers
  3. 2.3 Angiotensin Receptor Blockers (ARBs) Industry Opportunities and Challenges
  4. 2.4 Angiotensin Receptor Blockers (ARBs) Industry Restraints
3 Angiotensin Receptor Blockers (ARBs) Market by Company
  1. 3.1 Global Angiotensin Receptor Blockers (ARBs) Company Revenue Ranking in 2025
  2. 3.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Company (2021-2026)
  3. 3.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Company (2021-2026)
  4. 3.4 Global Angiotensin Receptor Blockers (ARBs) Average Price by Company (2021-2026)
  5. 3.5 Global Angiotensin Receptor Blockers (ARBs) Company Ranking (2024-2026)
  6. 3.6 Global Angiotensin Receptor Blockers (ARBs) Company Manufacturing Base and Headquarters
  7. 3.7 Global Angiotensin Receptor Blockers (ARBs) Company Product Type and Application
  8. 3.8 Global Angiotensin Receptor Blockers (ARBs) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Angiotensin Receptor Blockers (ARBs) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Angiotensin Receptor Blockers (ARBs) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Angiotensin Receptor Blockers (ARBs) Market by Type
  1. 4.1 Angiotensin Receptor Blockers (ARBs) Type Introduction
  2. 4.1.1 Valsartan
  3. 4.1.2 Telmisartan
  4. 4.1.3 Losartan
  5. 4.1.4 Irbesartan
  6. 4.1.5 Olmesartan
  7. 4.1.6 Azilsartan
  8. 4.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type
  9. 4.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type
  13. 4.3.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2021-2032)
  15. 4.3.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type (2021-2032)
5 Angiotensin Receptor Blockers (ARBs) Market by Application
  1. 5.1 Angiotensin Receptor Blockers (ARBs) Application Introduction
  2. 5.1.1 Cardiovascular Diseases
  3. 5.1.2 Kidney Diseases
  4. 5.1.3 Hypertension
  5. 5.1.4 Other
  6. 5.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application
  7. 5.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application
  11. 5.3.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2021-2032)
  13. 5.3.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application (2021-2032)
6 Angiotensin Receptor Blockers (ARBs) Regional Sales and Value Analysis
  1. 6.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Region (2021-2032)
  3. 6.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021-2026
  4. 6.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Region (2027-2032)
  5. 6.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2027-2032)
  9. 6.5 Global Angiotensin Receptor Blockers (ARBs) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032)
  12. 6.6.2 North America Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032)
  15. 6.7.2 Europe Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032)
  21. 6.9.2 South America Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value Share by Country, 2025 VS 2032
7 Angiotensin Receptor Blockers (ARBs) Country-level Sales and Value Analysis
  1. 7.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
  4. 7.3.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026)
  5. 7.3.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Country (2027-2032)
  6. 7.4 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Angiotensin Receptor Blockers (ARBs) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Angiotensin Receptor Blockers (ARBs) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Angiotensin Receptor Blockers (ARBs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Angiotensin Receptor Blockers (ARBs) Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jhonson and Johnson
  14. 8.3.1 Jhonson and Johnson Company Information
  15. 8.3.2 Jhonson and Johnson Business Overview
  16. 8.3.3 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Portfolio
  18. 8.3.5 Jhonson and Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Angiotensin Receptor Blockers (ARBs) Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Angiotensin Receptor Blockers (ARBs) Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Angiotensin Receptor Blockers (ARBs) Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GSK Angiotensin Receptor Blockers (ARBs) Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Angiotensin Receptor Blockers (ARBs) Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Astra Zeneca
  62. 8.11.1 Astra Zeneca Company Information
  63. 8.11.2 Astra Zeneca Business Overview
  64. 8.11.3 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Portfolio
  66. 8.11.5 Astra Zeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiotensin Receptor Blockers (ARBs) Value Chain Analysis
  2. 9.1.1 Angiotensin Receptor Blockers (ARBs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiotensin Receptor Blockers (ARBs) Sales Mode & Process
  6. 9.2 Angiotensin Receptor Blockers (ARBs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiotensin Receptor Blockers (ARBs) Distributors
  9. 9.2.3 Angiotensin Receptor Blockers (ARBs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst